2017-LOHM-67912 | |
Fatty acids are essential components of overall cellular metabolism. Malonyl-CoA is a coenzyme known to play a key role in the synthesis of fatty acids. Inhibition of malonyl-CoA results in defects in the biosynthesis of fatty acid. Development of such specialized inhibitors have applications in medicine. Therefore, there is a need, especially in medicine, for specialized inhibitors. Researchers at Purdue University, with various manipulations of malonyl-CoA, developed synthesized molecules that inhibit enzymes related to fatty acid synthases. These inhibitions may be the solution to treating bacterial infections, cancer, and obesity related diseases. These inhibitors are unique in that they can be modified to inhibit fatty acid metabolism in a specific organism. Advantages: -One inhibitor has the potential to treat bacterial infections, cancer, and obesity related diseases -Custom modification for single organisms Potential Applications: -Treating drug-resistant bacteria -Cancer treatment -Treating obesity related disease |
|
|
|
Jun 5, 2019
Utility Patent
United States
(None)
(None)
Jun 6, 2018
Provisional-Patent
United States
(None)
(None)
Jun 6, 2017
Provisional-Patent
United States
(None)
(None)
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |